DURHAM, N.C., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat"), (Nasdaq:HTBX), a clinical stage cancer immunotherapy company, announces the appointment of Holbrook Kohrt, M.D., Ph.D., and Kapil Dhingra, M.D., to the company's scientific and clinical advisory board.
"We are pleased to have industry leaders, Drs. Kohrt and Dhingra, join the Heat team. They both bring a wealth of clinical and research experience in the field of oncology, further strengthening the advisory board we have assembled to help progress our programs," said Jeff Wolf, Chief Executive Officer of Heat Biologics. "We look forward to their strategic insights and contributions as Heat continues to develop novel drug candidates based on our proprietary ImPACT and ComPACT technology platforms."
Dr. Kohrt is Assistant Professor of Medicine, Division of Oncology, at the Stanford University School of Medicine, in Palo Alto, CA. He is a board certified medical oncologist and internist at the Stanford University Medical Center and a member of the Stanford Cancer Institute. His research is focused on developing novel therapeutic strategies to enhance anti-tumor immunity and on preclinical models of novel immunomodulatory antibodies. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar and American Society of Hematology Research Fellow. He holds a M.D. and Ph.D. from Stanford and has published 35 articles in peer-reviewed scientific journals.
Dr. Dhingra has over 25 years of experience in oncology clinical research and drug development, including nine years at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. He served in several management positions at Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to his time at Roche, Dr. Dhingra worked as a senior clinical research physician at Eli Lilly and Company, as well as served as Assistant Professor at MD Anderson Cancer Center and Clinical Associate Professor at Indiana University School of Medicine. Dr. Dhingra is currently managing member and founder of KAPital Consulting, a healthcare consulting firm, as well as serves as an advisor to and/or member of the board of the directors for several emerging life science companies. He holds an M.B.B.S. (equivalent to an M.D. in the U.S.) from the All India Institute of Medical Sciences.
About Heat Biologics, Inc.
Heat Biologics is a clinical-stage cancer immunotherapy company focused on developing its novel, "off-the-shelf" ImPACT™ and ComPACT therapeutic vaccines to combat a wide range of cancersi. Our therapies are designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens, together with a potent immune adjuvant called "gp96," to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer, as well as a Phase 1b trial of HS-110 (viagenpumatucel-L) in combination with a PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer. For more information please visit the company's website at www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the expected contributions of the new appointees and Heat's continued development of its novel drug candidates. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to successfully integrate the new scientific advisory board members, the ability for Heat's ImPACT and ComPACT therapy to perform as designed, the ability to enroll patients and complete the clinical trials on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2014 and Heat's other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
i ImPACT is a registered trademark of Heat Biologics, Inc.